A federal multidistrict litigation involving thousands of patients who received a synthetic big toe implant is now one of the most closely watched medical device cases of 2026. The Cartiva implant failure lawsuit has entered a critical phase following the February 2026 centralization of cases into MDL No. 3172 in the Eastern District of Arkansas. If you or someone you love received a Cartiva Synthetic Cartilage Implant (SCI) and later experienced implant failure, revision surgery, or permanent joint fusion, this article explains what you need to know about your legal rights and the narrow window available to file a claim.
What Is the Cartiva Implant and Why Is It Failing?
The Cartiva Synthetic Cartilage Implant, approved by the FDA in 2016, was designed and marketed as a motion-preserving alternative to traditional big toe fusion surgery. Made from polyvinyl alcohol hydrogel, the small cylindrical device was implanted directly into the metatarsophalangeal joint of the big toe to relieve pain from hallux rigidus, a degenerative joint condition. Surgeons and patients were drawn to the device because, unlike fusion, it promised preserved range of motion and a faster return to normal activity.
The manufacturer initially claimed a failure rate of approximately 13%. However, post-market data and reports compiled following an FDA Class II recall issued in October 2024 tell a dramatically different story. Later reports indicate that implant failure may affect up to two-thirds of patients — a failure rate nearly five times higher than what was originally marketed to surgeons and the public. This enormous discrepancy between advertised and actual performance is now central to the Cartiva implant failure lawsuit litigation unfolding in federal court.
The FDA Recall and What It Covers
In October 2024, the FDA issued a Class II recall covering all lots of the Cartiva Synthetic Cartilage Implant manufactured between July 2016 and October 2024. A Class II recall indicates a situation where use of the device may cause temporary or medically reversible adverse health consequences. The scope of this recall is sweeping — it covers essentially every Cartiva SCI implanted in the United States since the device received FDA clearance.
Patients eligible to participate in the Cartiva implant failure lawsuit generally include anyone who received a Cartiva SCI within that July 2016 to October 2024 manufacturing window and subsequently experienced device failure, underwent revision surgery, or was left with a permanent joint fusion. The recall confirmation provides critical evidentiary support for patients pursuing legal claims, as it reflects the FDA’s own determination that the device presented unacceptable risk.
MDL No. 3172: What Centralization Means for Your Case
On February 5, 2026, the U.S. Judicial Panel on Multidistrict Litigation centralized all federally filed Cartiva cases into MDL No. 3172 in the Eastern District of Arkansas. Multidistrict litigation consolidates cases with common factual questions before a single judge to streamline pretrial proceedings, including discovery, depositions, and expert witness coordination. This does not mean individual cases lose their identity — each plaintiff retains their own claim and potential for individual recovery.
As of June 2026, the MDL is approximately four months into active litigation. Courts have moved quickly into the discovery phase, meaning attorneys are now gathering internal company communications, clinical trial data, sales records, and adverse event reports. This discovery period is precisely when the strongest evidence is typically uncovered. Plaintiffs who file during this window benefit from coordinated discovery that individual litigants could not otherwise access. If you are considering a Cartiva implant failure lawsuit, joining the MDL during this active phase — rather than waiting — is strategically significant.
Key Statistics: Marketed Claims vs. Reported Outcomes
The gap between what Cartiva’s manufacturer represented and what patients actually experienced is at the core of this litigation. The table below summarizes the critical data points driving the Cartiva implant failure lawsuit.
| Data Point | Manufacturer Claim | Post-Recall / Reported Data |
|---|---|---|
| Implant Failure Rate | ~13% | Up to 66% (two-thirds of patients) |
| FDA Approval Year | 2016 | Recall issued October 2024 |
| Recall Lot Coverage | N/A | All lots July 2016 – October 2024 |
| MDL Centralization Date | N/A | February 5, 2026 (EDARK) |
| Device Material | Polyvinyl alcohol hydrogel | Hydrogel degradation linked to failure |
Plaintiffs’ attorneys argue that the manufacturer was aware of elevated failure rates but continued marketing the device using incomplete or inaccurate data. The allegation is not simply that the device failed — it is that physicians and patients were denied the accurate information needed to make informed medical decisions.
Why Implant Failure Causes Irreversible Harm
One of the most medically significant aspects of the Cartiva implant failure lawsuit is the nature of the harm caused when the device fails. Unlike some implanted devices that can simply be removed to restore a patient to their prior condition, the Cartiva SCI cannot be removed without consequence. During the original implantation procedure, bone is removed from the metatarsophalangeal joint to create space for the synthetic implant. When the device fails, that bone is already gone.
This means that patients whose Cartiva implant fails are not returned to their pre-surgery baseline. Instead, they typically require one of two paths: a second corrective procedure or, most commonly, a permanent fusion surgery with bone grafting. Fusion eliminates all natural joint motion in the big toe — the very outcome the Cartiva was supposed to prevent. Many patients are left with permanent functional limitations, chronic pain, and an inability to participate in activities they enjoyed before surgery. Estimating the full value of these losses can be complex; tools like this personal injury settlement calculator can help patients begin understanding the potential scope of their damages before consulting an attorney.
What Plaintiffs Are Alleging Against the Manufacturer
The legal theories underlying the Cartiva implant failure lawsuit are grounded in product liability and negligence law. Plaintiffs allege that the manufacturer failed to adequately research long-term device performance before and after receiving FDA approval. They further allege that company representatives were aware of elevated failure rates emerging from post-market data but continued marketing the Cartiva SCI using the original, more favorable 13% failure rate figure.
These allegations, if proven, support claims under multiple legal theories recognized by products liability law, including failure to warn, manufacturing defect, design defect, and fraudulent misrepresentation. Damages in these cases typically encompass costs of revision or fusion surgery, ongoing medical expenses, lost wages, diminished earning capacity, and pain and suffering. The permanent nature of the harm — especially in cases requiring bone grafting and fusion — strengthens arguments for significant long-term compensation.
Who Should File a Cartiva Implant Failure Lawsuit in 2026
Patients who may be eligible to file a Cartiva implant failure lawsuit generally share one or more of the following circumstances: they received a Cartiva SCI between 2016 and 2024; they experienced early implant failure, subsidence, or implant degradation; they underwent revision surgery or were told fusion is now necessary; or their surgeon informed them the device was no longer functioning as intended. Even patients who have not yet required revision surgery but have received a failure diagnosis should consult with legal counsel promptly.
Statutes of limitations for medical device product liability claims vary by state, but most range from two to four years from the date of injury or discovery of injury. With the MDL centralized in February 2026 and discovery actively underway, June 2026 represents a critical filing window. Waiting further risks missing applicable deadlines and losing the ability to join coordinated proceedings where evidence is currently being developed on behalf of all plaintiffs.
Frequently Asked Questions About the Cartiva Implant Failure Lawsuit
Who qualifies to file a Cartiva implant failure lawsuit in 2026?
Any patient who received a Cartiva Synthetic Cartilage Implant between July 2016 and October 2024 and subsequently experienced implant failure, required revision surgery, or was left requiring permanent joint fusion may qualify to file a Cartiva implant failure lawsuit. Eligibility is not limited to patients who have already had corrective procedures — patients with a documented failure diagnosis who have not yet undergone surgery may also have a viable claim. The October 2024 FDA Class II recall covering all lots within that manufacturing window provides a strong evidentiary foundation for eligible plaintiffs.
What compensation can Cartiva lawsuit plaintiffs recover?
Plaintiffs in a Cartiva implant failure lawsuit may seek compensation for revision surgery costs, fusion surgery and bone grafting expenses, future medical care, lost wages, diminished earning capacity, and pain and suffering. Because many patients face permanent loss of joint motion and long-term functional limitations, damage awards in these cases can be substantial. The permanent nature of the harm caused by bone removal during original implantation — which prevents restoration to a pre-surgery baseline — is a particularly important factor in calculating total damages.
What is MDL No. 3172 and how does it affect individual cases?
MDL No. 3172 is the federal multidistrict litigation into which all Cartiva Synthetic Cartilage Implant cases were centralized on February 5, 2026, in the Eastern District of Arkansas. Centralization allows pretrial proceedings — including discovery, expert testimony, and legal motions — to be coordinated efficiently before a single judge. Importantly, individual plaintiffs do not lose their separate claims; each case retains its own identity for purposes of trial and settlement. Joining the MDL during the current active discovery phase maximizes access to evidence being gathered on behalf of all plaintiffs collectively.
Why is the Cartiva failure rate so much higher than what was marketed?
The manufacturer initially represented a failure rate of approximately 13%. However, post-market surveillance data and reports compiled in the context of the October 2024 FDA recall indicate that implant failure may affect up to two-thirds — roughly 66% — of patients. Plaintiffs allege that the manufacturer was aware of elevated failure rates emerging from real-world use but continued marketing the device using the original, more favorable data. These allegations of inadequate post-market research and continued use of incomplete data form the foundation of negligence and failure-to-warn claims in the Cartiva implant failure lawsuit.
How long do I have to file a Cartiva implant failure lawsuit?
Statutes of limitations for medical device product liability claims vary by state, typically ranging from two to four years from the date of injury or the date on which the injury was discovered or reasonably should have been discovered. With MDL No. 3172 centralized in February 2026 and active discovery now underway, the current period represents a strategically important window for filing. Patients who delay risk missing their state’s applicable deadline and losing the ability to participate in coordinated litigation. Consulting with a personal injury attorney as soon as possible is strongly recommended.
This article is provided for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction for advice specific to your situation.
Related reading: Cardiology Protocol Failure Verdict: $50 Million Award For Negligent Treatment Decision Post-Catheterization
Related reading: Tesla’s Speed Limiter Settlement: How Product Liability Wrongful Death Damages Are Calculated When A Passenger Had Zero Control
Thomas B. Harrison is a personal injury legal consultant with extensive experience connecting injury victims with qualified attorneys across the United States. He specializes in helping people understand when they need legal representation and how to find the right personal injury attorney for their specific situation. Thomas is not an attorney and the information he provides is for educational purposes only.